Supporting the designation of July as Uterine Fibroids Awareness Month.
H. Res. 579 is a nonbinding House resolution that supports designating July as Uterine Fibroids Awareness Month. It lays out findings about uterine fibroids, including that they can cause pelvic pain, abnormal uterine bleeding, reproductive dysfunction, miscarriages, infertility, and broader quality-of-life impacts. The resolution also cites the high prevalence of fibroids, the difficulty of early diagnosis, and the disproportionate burden on Black and Hispanic women.
The resolution does not create a new program or mandate changes to medical coverage, treatment, or reporting requirements. Instead, it expresses the sense of the House that there should be greater public awareness, research, treatment options, and education about uterine fibroids, and it encourages the President to issue a proclamation recognizing the month with appropriate awareness and educational activities.
Because this is a resolution, its legal effect is limited: it does not amend the U.S. Code, impose regulatory duties, or directly change state law. Its practical impact is symbolic and advocacy-oriented, aiming to elevate awareness of uterine fibroids, encourage education campaigns, and highlight disparities in diagnosis and treatment, especially for Black and Hispanic women. It may indirectly influence public health messaging, research priorities, and patient advocacy efforts, but it does not itself alter statutes governing healthcare, insurance, or medical practice.
The available context shows broadly supportive sentiment. The resolution is sponsored by a large bipartisan and bicameral-style coalition of House members, and its findings frame uterine fibroids as a significant women’s health issue with substantial medical, economic, and equity implications. There are no recorded committee transcripts or votes in the provided context, so there is no evidence of opposition in the materials supplied.
No specific contention is documented in the provided record. The resolution’s emphasis on racial disparities, the need for more research and treatment options, and the call for presidential recognition are the main substantive points, but no member objections, amendments, or divided votes are shown. If any debate were to arise, it would most likely concern the scope of federal involvement in awareness campaigns versus direct healthcare policy, but that is not reflected in the available materials.